In response to the public outbreak of the new coronavirus worldwide in 2019. Gilead is currently working closely with global medical. And health regulatory agencies to advance clinical trials of our antiviral drug redeliver. Gilead is willing to contact the US Food and Drug Administration (FDA). The US Centers for Disease Control and Prevention (CDC). The US Department of Health and Human Services (DHHS). China CDC. The World Health Organization (WHO). The US National Allergy and Infectious Diseases The Institute (NIAID). As well as individual researchers and clinicians. Work together to put our past antiviral drug development experience. And resources into this battle to help patients and institutions around the world fight COVID-19 together.
Gilead is working with China’s health department to conduct a randomized. A controlled trial to determine whether the use of Remdesivir in the treatment of COVID-19 infection is safe and effective. At the same time, appropriate laboratory testing of Remdesivir using COVID-19 virus samples is also being promoted.
What medicine is it?
Remdesivir is a nucleoside analog and is an RNA-dependent RNA polymerase (RdRp) inhibitor. It can achieve antiviral effects by inhibiting the synthesis of viral nucleic acids. Clinical studies on Ebola virus infection are currently in phase II.
In fact, this drug itself is not a drug for this COVID-19 coronavirus outbreak study. Friends who have a bit of medical knowledge know that drug development cannot be so fast. It is a drug developed by Gilead for the Ebola virus.
In preclinical studies, the drug was found to inhibit the Ebola virus’s protein called RdRP-a protein that is essential for replication. And reproduction of the Ebola virus in human cells. So it can play a strong role in Virus suppression.
Can patients in our country also use Remdesivir?
The situation in China is obviously different from that in the United States. There are a large number of patients with new coronary pneumonia. And it is not particularly difficult to design and complete a single clinical trial. Most patients are mild patients. And do not need to use new treatments with high unknown risks.
So it’s already clear how Radixivir is used in China:
Some of the drugs donated by Gilead are used to rescue critically ill patients with new coronary pneumonia (the China Drug Administration has passed the Chinese version of the sympathetic medication program in 2017. And this operation has rules to follow). And the other part is used to carry out regular human clinical Tests to determine as soon as possible whether it is safe. And effective for patients with new coronavirus pneumonia.
If the effect is indeed safe and easy to use. Then the scope of use of this drug can be greatly expanded to benefit more patients. If the effect is not good. Then the risks can be known in the first place and the “sympathetic medication” can be stopped in time.
In fact, good news has come. Gilead’s randomized, double-blind. The controlled phase III clinical trial of Radixvir in China has been launched at the speed of light. The total sample size is 270 patients, including patients with mild to moderate neo-coronary pneumonia. The trial began on February 3 and ended on April 27.
Cooperation is the only correct choice for China and the United States
The world is diverse, and there can be no world without differences. The practice of the 40 years since the establishment of diplomatic relations between China and the United States. Has proven that only by cooperating with each other can the benefits be maximized. Over the past 40 years. The two parties have achieved fruitful commercial results through both trade projects, and two-way investment projects. Both trade in goods and services. Involving the “Belt and Road” construction, energy, chemicals, environmental protection, culture, medicine, electronics, injection molds, Plastic products, infrastructure, and smart cities.
Sino-US relations are related to the well-being of the two peoples. And also to world peace, stability, and prosperity. Cooperation is the only correct choice between China and the United States. And a win-win situation can lead to a better future.
1. Remdesivir was originally a drug for Ebola virus research. Not for this new coronavirus study.
2. Remdesivir targets the new coronavirus (COVID-19) for further clinical research. And it cannot be called a specific drug for the COVID-19.
3. The use of Remdesivir in the United States to cure the first case of patients with pneumococcal pneumonia is not enough to prove that Remdesivir is effective for papillomavirus.
4. Regardless, Remdesivir is a drug that is currently promising to treat COVID-19. Gilead Pharmaceuticals has launched clinical research in cooperation with global health regulators. Phase III clinical trials in China have begun on February 3. Looking forward to the final effect.